Calamos Advisors LLC Invests $1.56 Million in PROCEPT BioRobotics Corporation $PRCT

Calamos Advisors LLC purchased a new stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 27,142 shares of the company’s stock, valued at approximately $1,563,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in PROCEPT BioRobotics by 32.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after purchasing an additional 270 shares during the last quarter. CWM LLC lifted its holdings in shares of PROCEPT BioRobotics by 40.7% during the second quarter. CWM LLC now owns 1,228 shares of the company’s stock valued at $71,000 after purchasing an additional 355 shares in the last quarter. Assetmark Inc. boosted its position in shares of PROCEPT BioRobotics by 5.1% during the second quarter. Assetmark Inc. now owns 8,333 shares of the company’s stock valued at $480,000 after buying an additional 407 shares during the last quarter. Arizona State Retirement System increased its holdings in PROCEPT BioRobotics by 3.2% in the 1st quarter. Arizona State Retirement System now owns 14,737 shares of the company’s stock worth $859,000 after buying an additional 452 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in PROCEPT BioRobotics in the 1st quarter worth about $30,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Stock Down 1.1%

Shares of PRCT stock opened at $30.42 on Friday. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics Corporation has a 12 month low of $29.78 and a 12 month high of $100.89. The stock has a market cap of $1.70 billion, a P/E ratio of -19.88 and a beta of 0.98. The company has a 50 day simple moving average of $35.37 and a two-hundred day simple moving average of $47.04.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. The firm had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

PRCT has been the topic of a number of recent analyst reports. Wells Fargo & Company dropped their price target on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. BTIG Research restated a “neutral” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, September 16th. Truist Financial cut their target price on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. TD Cowen lowered their price target on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Wall Street Zen downgraded PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.78.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).